Table III.
Significance of the mean methylation of MSP-methylated cervical lesions compared with that of MSP-unmethylated control samples for the investigated nucleotides.
| Nucleotide | P-value and lower bound of 95% CI |
|---|---|
| −57 | 0.0409*; 0.0017 |
| −52 | 0.0648; −0.0025 |
| −45 | 0.0093*; 0.0107 |
| −36 | 0.1375; −0.0080 |
| −13 | 0.0196*; 0.0090 |
| +6 | 0.0654; −0.0017 |
| +9 | 0.0462*; 0.0005 |
| +36 | 0.1032; −0.0069 |
| +60 | 0.1086; −0.0078 |
| +70 | 0.0358*; 0.0033 |
| +75 | 0.0381*; 0.0021 |
| +80 | 0.0278*; 0.0053 |
| +84 | 0.0683; −0.0031 |
| +90 | 0.0671; −0.0029 |
| +93 | 0.0438*; 0.0010 |
| +103 | 0.1383; −0.0127 |
| +107 | 0.1963; −0.0153 |
| +110 | 0.0243*; 0.0034 |
| +116 | 0.1256; −0.0114 |
H0 (null hypothesis), the mean methylation level of sample with MSP methylated CDH1 is equal to the mean methylation level of MSP unmethylated control sample; HA, the mean for MSP methylated CDH1 promoter is higher than the mean of MSP unmethylated control sample. P-value for the Welch's two sample t-test and lower bound of the one-sided 95% confidence interval. CI, confidence interval; MSP, methylation-specific polymerase chain reaction.